Literature DB >> 19651528

Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission.

Xiao-Feng Yang1, Steven M Rothman.   

Abstract

We recently reported that rodent hippocampal slices incubated with levetiracetam for 3h had altered responses to repetitive stimulation and reduced neurotransmitter release. However, our experiments failed to determine the actual time course of diminished transmission in individual slices followed over time. We have now been able to record from the same slices for up to 3h to determine the latency of the levetiracetam effect after the onset of exposure. Within 30 min of levetiracetam exposure, the later field potentials of a burst were reduced. Between 60 and 180 min the relative size of later field potentials remained stable. Similar time-dependent reductions were not seen in control slices or in slices exposed to the inactive levetiracetam isomer UCB L060. These new results establish a clear time dependence of the levetiracetam effect, even in vitro, and are best explained by levetiracetam acting within neurons to alter synaptic vesicle release.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651528     DOI: 10.1016/j.seizure.2009.07.004

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  15 in total

1.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

Review 2.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

3.  A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam.

Authors:  Anna L Meehan; Xiaofeng Yang; Brian D McAdams; Lilian Yuan; Steven M Rothman
Journal:  J Neurophysiol       Date:  2011-06-08       Impact factor: 2.714

4.  Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2018-10-06       Impact factor: 8.739

Review 5.  Levetiracetam in neonatal seizures: a review.

Authors:  Allison L Mruk; Karen L Garlitz; Noelle R Leung
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

Review 6.  Synaptic vesicle protein 2: A multi-faceted regulator of secretion.

Authors:  Kristine Ciruelas; Daniele Marcotulli; Sandra M Bajjalieh
Journal:  Semin Cell Dev Biol       Date:  2019-03-21       Impact factor: 7.727

7.  Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.

Authors:  Eric W Fish; Abigail E Agoglia; Michael C Krouse; R Grant Muller; J Elliott Robinson; C J Malanga
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

8.  Levetiracetam has opposite effects on alcohol- and cocaine-related behaviors in C57BL/6J mice.

Authors:  J Elliott Robinson; Meng Chen; Alice M Stamatakis; Michael C Krouse; Elaina C Howard; Sara Faccidomo; Clyde W Hodge; Eric W Fish; C J Malanga
Journal:  Neuropsychopharmacology       Date:  2013-01-25       Impact factor: 7.853

9.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.

Authors:  Pascal E Sanchez; Lei Zhu; Laure Verret; Keith A Vossel; Anna G Orr; John R Cirrito; Nino Devidze; Kaitlyn Ho; Gui-Qiu Yu; Jorge J Palop; Lennart Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

10.  Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.

Authors:  Amy Nowack; Erik B Malarkey; Jia Yao; Adam Bleckert; Jessica Hill; Sandra M Bajjalieh
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.